ResearcherHospital Clínic de BarcelonaNo recent work listed
Joan Maurel Santasusana
Matched on ORCID iD 0000-0002-9413-5592; OpenAlex author ID A5028687949. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 41
2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers
Papers 8
- Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Co-author DOI 10.1002/cam4.6621↗
- Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology. Co-author DOI 10.3389/fmolb.2023.1161893↗
- Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
- Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD… Co-author DOI 10.1007/s00280-018-3682-9↗
- Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis. Co-author DOI 10.1016/j.pan.2017.08.004↗
- SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Co-author DOI 10.1007/s12094-016-1586-x↗
- [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. Last author DOI 10.1016/j.medcli.2016.07.033↗
- A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Gru… Last author DOI 10.1371/journal.pone.0082209↗
Closest collaborators
The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Àngels Ginés Gibert · 4 shared papers, 2016–2023 · strength 0.32
- Paper Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology. DOI 10.3389/fmolb.2023.1161893↗
- Paper Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected… DOI 10.1016/j.pan.2017.08.004↗
- Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
- Glòria Fernández‐Esparrach · 3 shared papers, 2016–2023 · strength 0.26
- Paper Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology. DOI 10.3389/fmolb.2023.1161893↗
- Paper Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected… DOI 10.1016/j.pan.2017.08.004↗
- Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
- Eva Cristina Vaquero · 3 shared papers, 2016–2023 · strength 0.26
- Paper Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology. DOI 10.3389/fmolb.2023.1161893↗
- Paper Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected… DOI 10.1016/j.pan.2017.08.004↗
- Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
- Talia Golan · 1 shared paper, 2023 · strength 0.17
- Jean‐Frédéric Blanc · 1 shared paper, 2023 · strength 0.17
- Marc Peeters · 1 shared paper, 2023 · strength 0.17
- Chung‐Pin Li · 1 shared paper, 2023 · strength 0.17
- Vincent J. Picozzi · 1 shared paper, 2023 · strength 0.17
- Elena Gabriela Chiorean · 1 shared paper, 2023 · strength 0.17
- Howard S. Höchster · 1 shared paper, 2023 · strength 0.17
- Teresa Mercade Macarulla · 2 shared papers, 2016–2021 · strength 0.16
- Marta Martín-Richard · 3 shared papers, 2014–2018 · strength 0.15
- Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
- Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
- Paper A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unres… DOI 10.1371/journal.pone.0082209↗
- Fabio Ausania · 1 shared paper, 2023 · strength 0.15
- Leire Pedrosa · 1 shared paper, 2023 · strength 0.15
- Berta Laquente · 2 shared papers, 2016–2018 · strength 0.12
- Luis Sabater-Orti · 2 shared papers, 2016–2018 · strength 0.11
- Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
- Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
- Lisa M. Coussens · 1 shared paper, 2021 · strength 0.10
- Naureen Starling · 1 shared paper, 2021 · strength 0.10
- Andrew Eugene Hendifar · 1 shared paper, 2021 · strength 0.10
- Josep M. Tabernero · 1 shared paper, 2021 · strength 0.10
- Rocio García‐Carbonero · 1 shared paper, 2021 · strength 0.10
- Lawrence H. Fong · 1 shared paper, 2021 · strength 0.10
- Sara Lonardi · 1 shared paper, 2021 · strength 0.10
- Do‐Youn Oh · 1 shared paper, 2021 · strength 0.10
- Dirk Waldschmidt · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.